ISB News

Illustration of a person using a katana to slash a coronavirus in half

COVID-19 Immune Response Study Could Lead to More Effective Treatments

Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar. 

TCGA, ISB Researchers Identify Potential Drug Targets for Leading Form of Deadly Liver Cancer

June 19, 2017 Researchers in ISB’s Shmulevich Lab and their colleagues in The Cancer Genome Atlas Research Network performed the first large-scale, multi-platform analysis of hepatocellular carcinoma, the predominant form of liver cancer. Study was published on June 15, 2017, in the journal Cell. 3 Bullets: Liver cancer is the second most common cause of death from cancer worldwide. ISB researchers and colleagues from The Cancer Genome Atlas Research Network…

Largest Genetics Catalog of Deadliest Brain Tumor Released

  By Varsha Dhankani Glioblastoma multiforme (GBM) is the most common and deadliest of malignant primary brain tumors in adults. Because of its lethality, GBM was selected as the first brain tumor to be sequenced as part of The Cancer Genome Atlas (TCGA), a comprehensive project funded by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to map the genomes of more than 25 types…